• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Non-Sterile Compounding Pharmacy Market

    ID: MRFR/Pharma/3248-CR
    200 Pages
    Rahul Gotadki
    July 2025

    Non-Sterile Compounding Pharmacy Market Research Report By Application (Dermatology, Pediatrics, Pain Management, Hormone Replacement Therapy), By Formulation Type (Topical, Oral, Injection), By End Use (Hospital Pharmacies, Ambulatory Surgical Centers, Home Healthcare) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Non-Sterile Compounding Pharmacy Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Non-Sterile Compounding Pharmacy Market Summary

    As per Market Research Future analysis, the Non-Sterile Compounding Pharmacy Market was valued at 4.48 USD Billion in 2023 and is projected to grow to 6.8 USD Billion by 2035, with a CAGR of 3.54% from 2025 to 2035. The market is driven by the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and technological advancements in pharmacy practices.

    Key Market Trends & Highlights

    The Non-Sterile Compounding Pharmacy Market is witnessing significant growth due to several key trends.

    • The market is expected to reach 4.64 USD Billion in 2024, driven by personalized medicine and chronic disease management.
    • Dermatology segment valued at 0.987 USD Billion in 2024, projected to grow to 1.352 USD Billion by 2035.
    • Pediatrics segment anticipated to grow from 0.823 USD Billion in 2024 to 1.159 USD Billion by 2035.
    • North America leads the market with a valuation of 2.0 USD Billion in 2024, expected to reach 2.82 USD Billion by 2035.

    Market Size & Forecast

    2023 Market Size USD 4.48 Billion
    2024 Market Size USD 4.64 Billion
    2035 Market Size USD 6.8 Billion
    CAGR (2025-2035) 3.54%

    Major Players

    Key players include PharMEDium Services, Compounding Pharmacy of America, Pediatric Compounding Pharmacy, Rising Pharmaceuticals, Nephron Pharmaceuticals, Wockhardt, Perrigo Company, McGuff Pharmaceuticals, Accredo Health Group, Sonic Healthcare, Fagron, B. Braun Melsungen AG, and Fresenius Kabi.

    Non-Sterile Compounding Pharmacy Market Trends

    The Non-Sterile Compounding Pharmacy Market is experiencing notable growth driven by several key factors. The increasing need for personalized medication is a significant driver, as patients have unique health requirements that often cannot be met by commercially available drugs. This trend is reflected in the medical community's move toward customized treatment plans, which enhances patient care and medication adherence. Furthermore, there is a growing awareness of the benefits of compounding pharmacies among healthcare providers and patients, which has led to an increased demand for tailored formulations in various therapeutic areas.

    Opportunities within the market are expanding, especially with the rise of telehealth services and home healthcare solutions.

    By providing patients with convenient options for customized prescriptions, compounding pharmacies can meet the demand for accessible avenues for obtaining their medications. Compounding pharmacies are better equipped to address the changing demands of the global marketplace as a result of the continuous advancements in pharmaceutical technology and a robust supply chain. Recently, there has been an increased emphasis on regulatory compliance and quality assurance in the industry, as it is currently under scrutiny for its safety and efficacy.

    Governments and health organizations are increasingly emphasizing the establishment of regulations that guarantee the quality of compounded medications, thereby fostering an environment that emphasizes well-regulated compounding practices.

    The growth of the non-sterile compounding pharmacy market appears to be driven by an increasing demand for personalized medications and a rising awareness of the benefits of tailored pharmaceutical solutions.

    U.S. Food and Drug Administration (FDA)

    Non-Sterile Compounding Pharmacy Market Drivers

    Market Growth Projections

    The Global Non-Sterile Compounding Pharmacy Market Industry is projected to experience substantial growth over the coming years. With an estimated market value of 4.64 USD Billion in 2024, the industry is anticipated to reach 6.8 USD Billion by 2035. This growth trajectory suggests a robust compound annual growth rate (CAGR) of 3.54% from 2025 to 2035. Such projections indicate a favorable environment for compounding pharmacies, driven by increasing demand for personalized medications, advancements in technology, and supportive regulatory frameworks.

    Advancements in Pharmaceutical Technology

    Technological advancements play a crucial role in shaping the Global Non-Sterile Compounding Pharmacy Market Industry. Innovations in compounding techniques and equipment have improved the efficiency and safety of medication preparation. For instance, the adoption of automated compounding devices enhances precision and reduces the risk of human error. Furthermore, the integration of software solutions for inventory management and prescription processing streamlines operations. As these technologies continue to evolve, they are likely to drive growth in the market, which is expected to expand at a CAGR of 3.54% from 2025 to 2035.

    Increasing Prevalence of Chronic Diseases

    The Global Non-Sterile Compounding Pharmacy Market Industry is significantly influenced by the rising prevalence of chronic diseases. Conditions such as diabetes, hypertension, and arthritis require ongoing management, often necessitating customized medications. Compounding pharmacies are well-positioned to address these needs by providing formulations that may not be commercially available. This trend is expected to contribute to the market's growth, with projections indicating a rise to 6.8 USD Billion by 2035. The ability to create specific dosages and combinations tailored to individual patient requirements enhances treatment efficacy and patient satisfaction.

    Rising Demand for Personalized Medications

    The Global Non-Sterile Compounding Pharmacy Market Industry experiences a notable increase in demand for personalized medications. As healthcare becomes more patient-centric, the need for tailored therapies grows. Compounding pharmacies can create customized formulations that meet specific patient needs, such as unique dosages or alternative delivery methods. This trend is particularly evident in the treatment of chronic conditions, where individualized therapies can enhance patient compliance and outcomes. The market is projected to reach 4.64 USD Billion in 2024, reflecting the increasing reliance on compounding pharmacies to provide specialized medications.

    Regulatory Support for Compounding Practices

    Regulatory frameworks are evolving to support the Global Non-Sterile Compounding Pharmacy Market Industry. Government agencies are recognizing the importance of compounding pharmacies in providing essential medications, particularly for patients with unique needs. Initiatives aimed at streamlining regulations and ensuring quality standards are likely to bolster the market. For instance, the implementation of guidelines that promote best practices in compounding can enhance safety and efficacy, thereby increasing consumer trust. As regulations become more favorable, compounding pharmacies may experience growth opportunities, further solidifying their role in the healthcare system.

    Growing Awareness of Compounding Pharmacy Benefits

    There is a growing awareness among healthcare providers and patients regarding the benefits of compounding pharmacies within the Global Non-Sterile Compounding Pharmacy Market Industry. Educational initiatives and outreach programs are helping to inform stakeholders about the advantages of customized medications, such as improved adherence and reduced side effects. As more healthcare professionals recognize the value of compounding in patient care, the demand for these services is likely to increase. This heightened awareness may contribute to the market's expansion, as patients seek personalized solutions for their healthcare needs.

    Market Segment Insights

    Non-Sterile Compounding Pharmacy Market Application Insights

    The Non-Sterile Compounding Pharmacy Market, particularly within the Application segment, showcases a diverse range of medical needs addressed through various therapeutic areas. In 2024, the overall market is expected to be valued at 4.64 USD Billion, with significant contributions from specific applications such as Dermatology, Pediatrics, Pain Management, and Hormone Replacement Therapy.

    The Dermatology application, valued at 1.15 USD Billion in 2024, emphasizes the importance of personalized skincare solutions, addressing conditions such as eczema and psoriasis with compounded medications tailored to individual patient needs. This segment is anticipated to grow to a valuation of 1.75 USD Billion by 2035, indicating its dominant role in the market as skincare issues become increasingly prevalent in global populations.

    Pediatrics is another vital component of the market, holding a valuation of 1.1 USD Billion in 2024. This aspect of non-sterile compounding is crucial, as it involves the formulation of medications that are safe and effective for children, who often require dosages and forms not available in standard commercial products. By 2035, the Pediatrics segment is projected to grow to 1.65 USD Billion, reflecting the growing emphasis on specialized treatment options for younger patients.

    Pain Management, valued at 1.39 USD Billion in 2024, is significant, offering customized pain relief solutions for a wide range of conditions. The rise in chronic pain conditions is driving the demand for tailored compounding solutions, with the market set to reach 2.01 USD Billion by 2035, highlighting its critical importance in improving the quality of life for patients suffering from debilitating pain. Hormone Replacement Therapy, holding a value of 1.0 USD Billion in 2024, plays a crucial role in managing hormonal imbalances, especially among aging populations.

    The market for this application is expected to expand to 1.39 USD Billion by 2035, as more individuals seek tailored therapies for conditions related to menopause and andropause.

    Non-Sterile Compounding Pharmacy Market Formulation Type Insights

    The Non-Sterile Compounding Pharmacy Market is projected to reach a value of 4.64 billion USD by 2024, highlighting a significant demand in this sector. This market is primarily segmented by Formulation Type, which includes Topical, Oral, and Injection categories. The importance of these formulations is underscored by the growing prevalence of personalized medicine and the need for customized drug formulations. Topical solutions play a vital role in delivering localized treatment, making them essential for dermatological concerns. Oral formulations are typically favored for their convenience and ease of administration, contributing significantly to daily medication adherence.

    While Injection formulations are critical in various therapeutic areas, including pain management and vaccinations, the precise compounding of these formulations ensures safety and efficacy. Collectively, these factors are driving growth, supported by consumer preferences towards tailored pharmaceutical solutions. The Non-Sterile Compounding Pharmacy Market statistics indicate that the increasing focus on healthcare personalization and the rise of chronic diseases will further enhance the dynamics of this market segment.

    Non-Sterile Compounding Pharmacy Market End Use Insights

    The Non-Sterile Compounding Pharmacy Market, with a projected value of 4.64 billion USD in 2024, is experiencing noteworthy expansion, primarily driven by various end-use sectors. Hospital pharmacies play a crucial role in this market as they provide customized medications for inpatients, thus significantly contributing to the overall market growth. Ambulatory surgical centers also represent an important segment as they require tailored medications to enhance patient care following surgical procedures, thereby enabling outpatient recovery.

    Moreover, home healthcare is increasingly gaining traction, as it facilitates the administration of personalized medication regimens to patients in the comfort of their homes, addressing the growing demand for individualized treatment options. This trend is especially relevant as healthcare continues to evolve with a focus on patient-centered care. With the right policies and advancements in pharmacy practices, the Non-Sterile Compounding Pharmacy Market is positioned to thrive, providing valuable opportunities and addressing challenges within the healthcare landscape. Overall, the market segmentation showcases a diverse landscape that is essential for meeting the unique demands of patients across various healthcare settings.

    Get more detailed insights about Non-Sterile Compounding Pharmacy Market-Forecast Till 2035

    Regional Insights

    The Non-Sterile Compounding Pharmacy Market, valued at 4.64 USD Billion in 2024, shows a diverse regional distribution with varying growth potential. North America commands the majority holding with a valuation of 1.85 USD Billion in 2024, expected to reach 2.7 USD Billion by 2035, driven by advanced healthcare systems and increased demand for personalized medications. Europe follows, valued at 1.2 USD Billion in 2024, and projected to grow to 1.8 USD Billion, fueled by the rising elderly population and growing awareness of compounded medications.

    The Asian Pacific region, valued at 0.85 USD Billion in 2024, is gaining traction with an expected increase to 1.2 USD Billion, supported by expanding healthcare infrastructure and rising healthcare expenditure. South America and the Middle East and Africa present smaller markets, with valuations of 0.3 USD Billion and 0.44 USD Billion in 2024, respectively, but offer opportunities due to burgeoning pharmaceutical sectors. These regional dynamics illustrate the importance of localized strategies to cater to distinct healthcare demands and regulatory environments within the Non-Sterile Compounding Pharmacy Market.

    Non-Sterile Compounding Pharmacy Market Regional Insights

    Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

    Key Players and Competitive Insights

    The Non-Sterile Compounding Pharmacy Market is characterized by a diverse landscape of competitors that seek to meet the increasing demand for personalized medications and tailored pharmaceutical solutions. This market offers unique opportunities and challenges primarily driven by the growing appreciation for individualized patient care, advancements in pharmaceutical technology, and an evolving regulatory landscape. As healthcare continues to emphasize patient-centered approaches, the role of non-sterile compounding pharmacies becomes even more critical, necessitating a deeper understanding of competitive tactics, market positioning, and consumer needs.

    Stakeholders within this market must navigate a complex array of competitors who vary in size, service offerings, and geographic reach, each bringing distinct advantages and strategies to capture value.

    PCCA is a significant player in the Non-Sterile Compounding Pharmacy Market, renowned for its extensive portfolio of resources and products designed to serve compounding pharmacies. The company has cultivated a strong reputation by offering comprehensive support services, quality raw materials, and innovative formulations that empower pharmacists to create customized solutions tailored to specific patient requirements. PCCA's strength lies in its commitment to quality and education, providing pharmacists with the necessary tools and knowledge to excel in their compounding practices.

    Furthermore, PCCA's robust network and engagement with the compounding community enhance its market presence and solidify its position as a trusted partner for many pharmacies focusing on non-sterile compounding.

    PharMEDium Services represents another formidable competitor in the Non-Sterile Compounding Pharmacy Market, focusing on delivering high-quality compounding services that cater to a wide range of healthcare settings. PharMEDium offers a suite of key products and services, including sterile and non-sterile compounding critical to hospitals and outpatient settings. The company is recognized for its dedication to maintaining safety and efficacy through stringent quality control measures. PharMEDium's market presence is bolstered by strategic partnerships and an emphasis on continuous innovation, allowing it to stay ahead in the competitive landscape.

    Additionally, the company’s proactive approach includes engaging in mergers and acquisitions, aimed at expanding its capabilities and enhancing service offerings. This growth strategy enables PharMEDium Services to strengthen its position in the global market, furthering its mission to support healthcare providers and their patients with reliable and effective compounding solutions.

    Key Companies in the Non-Sterile Compounding Pharmacy Market market include

    Industry Developments

    • Q2 2024: Innovation Compounding Announces Opening of New State-of-the-Art Compounding Facility in Georgia Innovation Compounding, a pharmacy specializing in non-sterile compounding, announced the opening of a new facility in Georgia designed to expand its production capacity and improve quality control for customized medications.
    • Q1 2024: PCCA Appoints New Chief Executive Officer to Lead Expansion in Compounding Pharmacy Services Pharmacy Compounding Centers of America (PCCA) named a new CEO to drive strategic growth and innovation in non-sterile compounding pharmacy services, focusing on expanding partnerships with independent pharmacies.
    • Q2 2024: Fagron Acquires Central Pharmacy Services to Strengthen U.S. Non-Sterile Compounding Market Position Fagron, a global leader in pharmaceutical compounding, completed the acquisition of Central Pharmacy Services, enhancing its footprint and service offerings in the U.S. non-sterile compounding pharmacy sector.
    • Q3 2024: Wedgewood Pharmacy Launches New Line of Customized Dermatology Compounds for Veterinary Use Wedgewood Pharmacy introduced a new product line of non-sterile compounded dermatology medications for veterinary practices, expanding its portfolio of customized animal health solutions.
    • Q2 2025: PharmScript Partners with Medisca to Enhance Non-Sterile Compounding Capabilities in Long-Term Care Facilities PharmScript announced a strategic partnership with Medisca to improve non-sterile compounding services for long-term care facilities, focusing on tailored medication solutions for elderly patients.
    • Q1 2025: Belmar Pharma Solutions Receives State Regulatory Approval for Expanded Non-Sterile Compounding Operations Belmar Pharma Solutions secured regulatory approval from state authorities to expand its non-sterile compounding operations, enabling the company to serve a broader patient base with customized medications.
    • Q2 2024: CareFirst Pharmacy Secures $10 Million Series A Funding to Scale Non-Sterile Compounding Services CareFirst Pharmacy raised $10 million in Series A funding to invest in new technology and expand its non-sterile compounding pharmacy services across multiple states.
    • Q3 2024: Avella Specialty Pharmacy Announces Opening of New Non-Sterile Compounding Lab in Arizona Avella Specialty Pharmacy opened a new non-sterile compounding laboratory in Arizona, increasing its capacity to produce customized medications for patients with unique therapeutic needs.
    • Q1 2025: Pharmaca Integrative Pharmacy Launches Pediatric Non-Sterile Compounding Service Pharmaca Integrative Pharmacy launched a new pediatric non-sterile compounding service, offering customized formulations for children with specific dosage and allergy requirements.
    • Q2 2025: Guardian Pharmacy Services Acquires Compounding Solutions to Expand Non-Sterile Offerings Guardian Pharmacy Services acquired Compounding Solutions, a move aimed at broadening its non-sterile compounding capabilities and reaching more healthcare providers nationwide.
    • Q3 2024: Medisca Unveils New Training Program for Non-Sterile Compounding Pharmacists Medisca launched a new training initiative for pharmacists specializing in non-sterile compounding, designed to improve safety, compliance, and formulation expertise.
    • Q1 2024: Empower Pharmacy Receives FDA Registration for Non-Sterile Compounding Facility Empower Pharmacy announced FDA registration for its new non-sterile compounding facility, enabling the company to manufacture and distribute customized medications nationwide.

    Future Outlook

    Non-Sterile Compounding Pharmacy Market Future Outlook

    The Non-Sterile Compounding Pharmacy Market is projected to grow at a 3.54% CAGR from 2024 to 2035, driven by personalized medicine, regulatory advancements, and increasing demand for customized formulations.

    New opportunities lie in:

    • Invest in technology for automated compounding systems to enhance efficiency and accuracy.
    • Develop niche products targeting specific patient populations for tailored therapeutic solutions.
    • Expand partnerships with healthcare providers to increase market reach and patient access.

    By 2035, the Non-Sterile Compounding Pharmacy Market is expected to be robust, reflecting significant growth and innovation.

    Market Segmentation

    Non-Sterile Compounding Pharmacy Market End Use Outlook

    • Hospital Pharmacies
    • Ambulatory Surgical Centers
    • Home Healthcare

    Non-Sterile Compounding Pharmacy Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Non-Sterile Compounding Pharmacy Market Application Outlook

    • Dermatology
    • Pediatrics
    • Pain Management
    • Hormone Replacement Therapy

    Non-Sterile Compounding Pharmacy Market Formulation Type Outlook

    • Topical
    • Oral
    • Injection

    Report Scope

    Report Attribute/Metric

    Details

    Market Size 2023

    4.48(USD Billion)

    Market Size 2024

    4.64(USD Billion)

    Market Size 2035

    6.8(USD Billion)

    Compound Annual Growth Rate (CAGR)

    3.54% (2025 - 2035)

    Report Coverage

    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

    Base Year

    2024

    Market Forecast Period

    2025 - 2035

    Historical Data

    2019 - 2024

    Market Forecast Units

    USD Billion

    Key Companies Profiled

    PCCA, PharMEDium Services, Sigma Pharmaceuticals, Cencora, Fagron, Walgreens Boots Alliance, Renaissance Pharmacy, Cardinal Health, Eli Lilly and Company, Compounded Solutions, BioCare Copenhagen, Kroger Pharmacy, Parkdale Pharmacy, Avella Pharmacy

    Segments Covered

    Application, Formulation Type, End Use, Regional

    Key Market Opportunities

    Increasing demand for personalized medicine, Growth in chronic diseases prevalence, Rising regulatory support for compounding, Expanding geriatric population needs, Advances in compounding technology

    Key Market Dynamics

    Customization demand, Regulatory challenges, Rising chronic diseases, Technological advancements, Cost-effective solutions

    Countries Covered

    North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the Non-Sterile Compounding Pharmacy Market in 2024?

    The Non-Sterile Compounding Pharmacy Market is expected to be valued at 4.64 USD Billion in 2024.

    What market value is projected for the Non-Sterile Compounding Pharmacy Market by 2035?

    By 2035, the Non-Sterile Compounding Pharmacy Market is projected to be valued at 6.8 USD Billion.

    What is the expected CAGR for the Non-Sterile Compounding Pharmacy Market from 2025 to 2035?

    The expected CAGR for the Non-Sterile Compounding Pharmacy Market from 2025 to 2035 is 3.54%.

    Which region holds the largest market share in the Non-Sterile Compounding Pharmacy Market for 2024?

    North America holds the largest market share, valued at 1.85 USD Billion in 2024.

    What is the projected market value for the European region in the Non-Sterile Compounding Pharmacy Market by 2035?

    The European region's market value is projected to reach 1.8 USD Billion by 2035.

    What is the expected market size in the Asia Pacific region for the Non-Sterile Compounding Pharmacy Market in 2024?

    The Asia Pacific region is expected to have a market size of 0.85 USD Billion in 2024.

    Which application segment is expected to dominate the market by 2035?

    The Pain Management application segment is expected to dominate the market by reaching 2.01 USD Billion in 2035.

    What is the anticipated market growth for the Hormone Replacement Therapy application from 2024 to 2035?

    The Hormone Replacement Therapy application is anticipated to grow from 1.0 USD Billion in 2024 to 1.39 USD Billion by 2035.

    Who are the key players in the Non-Sterile Compounding Pharmacy Market?

    Key players in the market include PCCA, PharMEDium Services, Sigma Pharmaceuticals, and Walgreens Boots Alliance.

    What is the projected market value for Pediatrics application in the Non-Sterile Compounding Pharmacy Market by 2035?

    The projected market value for the Pediatrics application is 1.65 USD Billion by 2035.

    Non-Sterile Compounding Pharmacy Market-Forecast Till 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials